Top

European Archives of Psychiatry and Clinical Neuroscience

25-04-2024 | Ketamine | Original Paper

Ketamine and its enantiomers for depression: a bibliometric analysis from 2000 to 2023

Authors: Li-yuan Zhao, Guang-fen Zhang, Xue-jie Lou, Kenji Hashimoto, Jian-jun Yang

Published in: European Archives of Psychiatry and Clinical Neuroscience

Abstract

Ketamine has demonstrated rapid and sustained antidepressant effects, marking its emergence as an innovative treatment of depression. Despite the growing number of preclinical and clinical studies exploring the antidepressant effects of ketamine and its enantiomers, a comprehensive bibliometric analysis in this field has yet to be conducted. This study employs bibliometric methods and visualization tools to examine the literature and identify key topics related to the antidepressant effects of ketamine and its enantiomers. We sourced publications on the antidepressant effects of ketamine and its enantiomers from the Web of Science Core Collection (WOSCC) database, covering the period from 2000 to 2023. Tools such as VOSviewer, CiteSpace and the R package “bibliometrix” were utilized for visual analysis. The study included 4,274 publications, with a notable increase in publications peaking in 2022. Co-occurrence analysis highlighted two primary research focal points: the efficacy and safety of ketamine and its enantiomers in treating depression, and the mechanisms behind their antidepressant effects. In conclusion, this analysis revealed a significant increase in research on the antidepressant effects of ketamine and its enantiomers over the past two decades, leading to the approval of esketamine nasal spray for treatment-resistant depression. The rapid antidepressant effects of ketamine have spurred further studies into its mechanisms of action and the search for new antidepressants with fewer side effects.

Jick H, Kaye JA, Jick SS (2004) Antidepressants and the risk of suicidal behaviors. JAMA 292(3):338–343. https://doi.org/10.1001/jama.292.3.338CrossRefPubMed

Hashimoto K (2019) Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective. Psychiatry Clin Neurosci 73(10):613–627. https://doi.org/10.1111/pcn.12902CrossRefPubMedPubMedCentral

Hashimoto K (2020) Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine. Biochem Pharmacol 177:113935. https://doi.org/10.1016/j.bcp.2020.113935CrossRefPubMed

Hashimoto K (2022) (2022) Ketamine: anesthetic, psychotomimetic, antidepressant, or anthelmintic? Mol Psychiatry 27(8):3116–3118. https://doi.org/10.1038/s41380-022-01587-7CrossRefPubMed

Johnston JN, Henter ID, Zarate CA (2023) The antidepressant actions of ketamine and its enantiomers. Pharmacol Ther 246:108431. https://doi.org/10.1016/j.pharmthera.2023.108431CrossRefPubMed

Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47(4):351–354. https://doi.org/10.1016/s0006-3223(99)00230-9CrossRefPubMed

Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS (2006) Manji HK (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856–864. https://doi.org/10.1001/archpsyc.63.8.856CrossRefPubMed

Singh JB, Fedgchin M, Daly E, Xi LW, Melman C, De Bruecker G, Tadic A, Sienaert P, Wiegand F, Manji H, Drevets WC, Van Nueten L (2016) Intravenous esketamine in adult treatment-resistant depression: A double-blind, double-randomization, placebo-controlled study. Biol Psychiatry 80(6):424–431. https://doi.org/10.1016/j.biopsych.2015.10.018CrossRefPubMed

Su TP, Chen MH, Li CT, Lin WC, Hong CJ, Gueorguieva R, Tu PC, Bai YM, Cheng CM, Krystal JH (2017) Dose-related effects of adjunctive ketamine in Taiwanese patients with treatment-resistant depression. Neuropsychopharmacology 42(13):2482–2492. https://doi.org/10.1038/npp.2017.94CrossRefPubMedPubMedCentral

10.

Popova V, Daly EJ, Trivedi M, Cooper K, Lane R, Lim P, Mazzucco C, Hough D, Thase ME, Shelton RC, Molero P, Vieta E, Bajbouj M, Manji H, Drevets WC, Singh JB (2019) Efficacy and safety of flexibly dosed Esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry 176:428–438. https://doi.org/10.1176/appi.ajp.2019.19020172CrossRefPubMed

11.

Leal GC, Bandeira ID, Correia-Melo FS, Telles M, Mello RP, Vieira F, Lima CS, Jesus-Nunes AP, Guerreiro-Costa LNF, Marback RF, Caliman-Fontes AT, Marques BLS, Bezerra MLO, Dias-Neto AL, Silva SS, Sampaio AS, Sanacora G, Turecki G, Loo C, Lacerda ALT, Quarantini LC (2021) Eur Arch Psychiatry Clin Neurosci 271(3):577–582. https://doi.org/10.1007/s00406-020-01110-5CrossRefPubMed

12.

Zanos P, Gould TD (2018) Mechanisms of ketamine action as an antidepressant. Mol Psychiatry 23:801–811. https://doi.org/10.1038/mp.2017.255CrossRefPubMedPubMedCentral

13.

Yang C, Ren Q, Qu Y, Zhang JC, Ma M, Dong C, Hashimoto K (2018) Mechanistic target of rapamycin-independent antidepressant effects of (R)-ketamine in a social defeat stress model. Biol Psychiatry 83(1):18–28. https://doi.org/10.1016/j.biopsych.2017.05.016CrossRefPubMed

14.

Yang C, Yang J, Luo A, Hashimoto K (2019) Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites. Transl Psychiatry 9(1):280. https://doi.org/10.1038/s41398-019-0624-1CrossRefPubMedPubMedCentral

15.

Zhang K, Yang C, Chang L, Sakamoto A, Suzuki T, Fujita Y, Qu Y, Wang S, Pu Y, Tan Y, Wang X, Ishima T, Shirayama Y, Hatano M, Tanaka KF, Hashimoto K (2020) Essential role of microglial transforming growth factor-β1 in antidepressant actions of (R)-ketamine and the novel antidepressant TGF-β1. Transl Psychiatry 10(1):32. https://doi.org/10.1038/s41398-020-0733-xCrossRefPubMedPubMedCentral

16.

Wei Y, Chang LJ, Hashimoto K (2022) Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor. Mol Psychiatry 27(1):559–573. https://doi.org/10.1038/s41380-021-01121-1CrossRefPubMed

17.

Zhang JC, Yao W, Hashimoto K (2022) Arketamine, a new rapid-acting antidepressant: a historical review and future directions. Neuropharmacology 218:109219. https://doi.org/10.1016/j.neuropharm.2022.109219CrossRefPubMed

18.

Zhang K, Yao Y, Hashimoto K (2023) Ketamine and its metabolites: Potential as novel treatments for depression. Neuropharmacology 222:109305. https://doi.org/10.1016/j.neuropharm.2022.109305CrossRefPubMed

19.

Yao W, Cao Q, Luo S, He L, Yang C, Chen J, Qi Q, Hashimoto K, Zhang JC (2022) Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine. Mol Psychiatry 27(3):1618–1629. https://doi.org/10.1038/s41380-021-01377-7CrossRefPubMed

20.

Huang C, Wu Z, Wang D, Qu Y, Zhang J, Jiang R, Xu X, Xu X, Wang Y, Liu H, He T, Liu C, Chen G, Yang JJ, Hashimoto K (2023) Myelin-associated oligodendrocytic basic protein-dependent myelin repair confers the long-lasting antidepressant effect of ketamine. Mol Psychiatry. https://doi.org/10.1038/s41380-023-02288-5CrossRefPubMedPubMedCentral

21.

Zhang JC, Li SX, Hashimoto K (2014) R(-)-ketamine shows greater potency and longer lasting antidepressant effects than S(+)-ketamine. Pharmacol Biochemi Behav 116:137–141. https://doi.org/10.1016/j.pbb.2013.11.033CrossRef

22.

Yang C, Shirayama Y, Zhang JC, Ren Q, Yao W, Ma M, Dong C, Hashimoto K (2015) R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry 5(9):e632. https://doi.org/10.1038/tp.2015.136CrossRefPubMedPubMedCentral

23.

Chang L, Zhang K, Pu Y, Qu Y, Wang S, Xiong Z, Ren Q, Dong C, Fujita Y, Hashimoto K (2019) Comparison of antidepressant and side effects in mice after intranasal administration of (R, S)-ketamine, (R)-ketamine, and (S)-ketamine. Pharmacol Biochem Behav 181:53–59. https://doi.org/10.1016/j.pbb.2019.04.008CrossRefPubMed

24.

He T, Wang D, Wu Z, Huang C, Xu X, Xu X, Liu C, Hashimoto K, Yang C (2022) A bibliometric analysis of research on (R)-ketamine from 2002 to 2021. Neuropharmacology 218:109207. https://doi.org/10.1016/j.neuropharm.2022.109207CrossRefPubMed

25.

He T, Wu Z, Zhang X, Liu H, Wang Y, Jiang R, Liu C, Hashimoto K, Yang C (2022) A bibliometric analysis of research on the role of BDNF in depression and treatment. Biomolecules 12(10):1464. https://doi.org/10.3390/biom12101464CrossRefPubMedPubMedCentral

26.

Miao H, Yu K, Gao D, Lin X, Cao Y, Liu X, Qiao H, Li T (2022) A bibliometric analysis of research on ketamine from 2001 to 2020. Front Mol Neurosci 15:839198. https://doi.org/10.3389/fnmol.2022.839198CrossRefPubMedPubMedCentral

27.

Grover S, Gupta BM (2022) Global research on Obsessive Compulsive Disorder and related disorders: A scientometric assessment of global research during 2002–2021. Asian J Psychiatry 72:103146. https://doi.org/10.1016/j.ajp.2022.103146CrossRef

28.

Zhou W, Bai X, Yang Y, Huang M, Zheng Q, Wu J, Wang R, Gan X (2023) Revelations of delirium subtype research: a bibliometric analysis of publications in the past twenty years in the field. Asian J Psychiatry 83:103561. https://doi.org/10.1016/j.ajp.2023.103561CrossRef

29.

van Eck NJ, Waltman L (2010) Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics 84(2):523–538. https://doi.org/10.1007/s11192-009-0146-3CrossRefPubMed

30.

Chen C (2004) Searching for intellectual turning points: progressive knowledge domain visualization. Proc Nat Acad Sci USA 101(Suppl 1):5303–5310. https://doi.org/10.1073/pnas.0307513100CrossRefPubMedPubMedCentral

31.

Chen C (2006) CiteSpace II: Detecting and visualizing emerging trends and transient patterns in scientific literature. J Am Soc Inform Sci Technol 57(3):359–377. https://doi.org/10.1002/asi.20317CrossRef

32.

Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, Alkondon M, Yuan PX, Pribut HJ, Singh NS, Dossou KSS, Fang YH, Huang XP, Mayo CL, Wainer IW, Albuquerque EX, Thompson SM, Thomas CJ, Zarate CA, Gould TD (2016) NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 533(7604):481–486. https://doi.org/10.1038/nature17998CrossRefPubMedPubMedCentral

33.

Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, Kavalali ET, Monteggia LM (2011) NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475(7354):91–95. https://doi.org/10.1038/nature10130CrossRefPubMedPubMedCentral

34.

Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, Li XY, Aghajanian G, Duman RS (2010) mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329(5994):959–964. https://doi.org/10.1126/science.1190287CrossRefPubMedPubMedCentral

35.

Duman RS, Aghajanian GK (2012) Synaptic dysfunction in depression: potential therapeutic targets. Science 338(6103):68–72. https://doi.org/10.1126/science.1222939CrossRefPubMedPubMedCentral

36.

Hadar A, David J, Shalit N, Roseman L, Gross R, Sessa B, Lev-Ran S (2023) The psychedelic renaissance in clinical research: A bibliometric analysis of three decades of human studies with psychedelics. J Psychoactive Drugs 55(1):1–10. https://doi.org/10.1080/02791072.2021.2022254CrossRefPubMed

37.

Hashimoto K (2024) Are “mystical experiences” essential for antidepressant actions of ketamine and classic psychedelics? Eur Arch Psychiatry Clin Neurosci in press. https://doi.org/10.1007/s00406-024-01770-7CrossRef

38.

Solmi M, Chen C, Daure C, Buot A, Ljuslin M, Verroust V, Mallet L, Khazaal Y, Rothen S, Thorens G, Zullino D, Gobbi G, Rosenblat J, Husain MI, De Gregorio D, Castle D, Sabé M (2022) A century of research on psychedelics: A scientometric analysis on trends and knowledge maps of hallucinogens, entactogens, entheogens and dissociative drugs. Eur Neuropsychopharmacol 64:44–60. https://doi.org/10.1016/j.euroneuro.2022.09.004CrossRefPubMed

39.

Domino EF (2010) Taming the ketamine tiger. Anesthesiology 113(3):678–684. https://doi.org/10.1097/ALN.0b013e3181ed09a2CrossRefPubMed

40.

Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, Kammerer WA, Quezado Z, Luckenbaugh DA, Salvadore G, Machado-Vieira R, Manji HK, Zarate CA Jr (2010) A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 67(8):93–802. https://doi.org/10.1001/archgenpsychiatry.2010.90CrossRef

41.

Ibrahim L, DiazGranados N, Franco-Chaves J, Brutsche N, Henter ID, Kronstein P, Moaddel R, Wainer I, Luckenbaugh DA, Manji HK, Zarate CA (2012) Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology 37(6):1526–1533. https://doi.org/10.1038/npp.2011.338CrossRefPubMedPubMedCentral

42.

Zarate CA, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A, Selter J, Marquardt CA, Liberty V, Luckenbaugh DA (2012) Replication of ketamine’s antidepressant efficacy in bipolar depression: A randomized controlled add-on trial. Biol Psychiatry 71(11):939–946. https://doi.org/10.1016/j.biopsych.2011.12.010CrossRefPubMedPubMedCentral

43.

Machado-Vieira R, Salvadore G, DiazGranados N, Zarate CA (2009) Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther 123(2):143–150. https://doi.org/10.1016/j.pharmthera.2009.02.010CrossRefPubMedPubMedCentral

44.

Lener MS, Niciu MJ, Ballard ED, Park M, Park LT, Nugent AC, Zarate CA (2017) Glutamate and gamma-aminobutyric acid systems in the pathophysiology of major depression and antidepressant response to ketamine. Biol Psychiatry 81(10):886–897. https://doi.org/10.1016/j.biopsych.2016.05.005CrossRefPubMed

45.

Bahji A, Vazquez GH, Zarate CA (2021) Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. J Affect Disord 278:542–555. https://doi.org/10.1016/j.jad.2020.09.071CrossRefPubMed

46.

Fukumoto K, Toki H, Iijima M, Hashihayata T, Yamaguchi J, Hashimoto K, Chaki S (2017) Antidepressant potential of (R)-ketamine in rodent models: comparison with (S)-ketamine. J Pharmacol Exp Ther 361(1):9–16. https://doi.org/10.1124/jpet.116.239228CrossRefPubMed

47.

Yang C, Qu Y, Abe M, Nozawa D, Chaki S, Hashimoto K (2017) (R)-Ketamine shows greater potency and longer lasting antidepressant effects than its metabolite (2R,6R)-hydroxynorketamine. Biol Psychiatry 82(5):e43–e44. https://doi.org/10.1016/j.biopsych.2016.12.020CrossRefPubMed

48.

Shirayama Y, Hashimoto K (2018) Lack of antidepressant effects of (2R,6R)-hydroxynorketamine in a rat learned helplessness model: comparison with (R)-ketamine. Int J Neuropsychopharmacol 21(1):84–88. https://doi.org/10.1093/ijnp/pyx108CrossRefPubMed

49.

Yamaguchi JI, Toki H, Qu Y, Yang C, Koike H, Hashimoto K, Mizuno-Yasuhira A, Chaki S (2018) (2R,6R)-Hydroxynorketamine is not essential for the antidepressant actions of (R)-ketamine in mice. Neuropsychopharmacology 43(9):1900–1907. https://doi.org/10.1038/s41386-018-0084-yCrossRefPubMedPubMedCentral

50.

Zhang K, Fujita Y, Hashimoto K (2018) Lack of metabolism in (R)-ketamine’s antidepressant actions in a chronic social defeat stress model. Sci Rep 8(1):4007. https://doi.org/10.1038/s41598-018-22449-9CrossRefPubMedPubMedCentral

51.

Zhang K, Toki H, Fujita Y, Ma M, Chang L, Qu Y, Harada S, Nemoto T, Mizuno-Yasuhira A, Yamaguchi JI, Chaki S, Hashimoto K (2018) Lack of deuterium isotope effects in the antidepressant effects of (R)-ketamine in a chronic social defeat stress model. Psychopharmacology 235(11):3177–3185. https://doi.org/10.1007/s00213-018-5017-2CrossRefPubMed

52.

Daly EJ, Trivedi MH, Janik A, Li HL, Zhang Y, Li X, Lane R, Lim P, Duca AR, Hough D, Thase ME, Zajecka J, Winokur A, Divacka I, Fagiolini A, Cubala WJ, Bitter I, Blier P, Shelton RC, Molero P, Manji H, Drevets WC, Singh JB (2019) Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: A randomized clinical trial. JAMA Psychiat 76(9):893–903. https://doi.org/10.1001/jamapsychiatry.2019.1189CrossRef

53.

Turner EH (2019) Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval. Lancet Psychiatry 6(12):977–979. https://doi.org/10.1016/S2215-0366(19)30394-3CrossRefPubMed

54.

Jiang Y, Du Z, Shen Y, Zhou Q (2023) Zhu H (2023) The correlation of Esketamine with specific adverse events: a deep dive into the FAERS database. Eur Arch Psychiatry Clin Neurosci. https://doi.org/10.1007/s00406-023-01732-5CrossRefPubMedPubMedCentral

55.

Camargo A, Dalmagro AP, Wolin IAV, Siteneski A, Zeni ALB, Rodrigues ALS (2021) A low-dose combination of ketamine and guanosine counteracts corticosterone-induced depressive-like behavior and hippocampal synaptic impairments via mTORC1 signaling. Prog Neuropsychopharmacol Biol Psychiatry 111:110371. https://doi.org/10.1016/j.pnpbp.2021.110371CrossRefPubMed

56.

Kishimoto T, Chawla JM, Hagi K, Zarate CA, Kane JM, Bauer M, Correll CU (2016) Single-dose infusion ketamine and non-ketamine N-methyl-D-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. Psychol Med 46(7):1459–1472. https://doi.org/10.1017/S0033291716000064CrossRefPubMedPubMedCentral

57.

Fukumoto K, Iijima M, Chaki S (2016) The antidepressant effects of an mGlu2/3 receptor antagonist and ketamine require AMPA receptor stimulation in the mPFC and subsequent activation of the 5-HT neurons in the DRN. Neuropsychopharmacology 41(4):1046–1056. https://doi.org/10.1038/npp.2015.233CrossRefPubMed

58.

Gerhard DM, Pothula S, Liu RJ, Wu M, Li XY, Girgenti MJ, Taylor SR, Duman CH, Delpire E, Picciotto M, Wohleb ES, Duman RS (2020) GABA interneurons are the cellular trigger for ketamine’s rapid antidepressant actions. J Clin Invest 130(3):1336–1349. https://doi.org/10.1172/JCI130808CrossRefPubMedPubMedCentral

59.

Pham TH, Gardier AM (2019) Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies. Pharmacol Ther 199:58–90. https://doi.org/10.1016/j.pharmthera.2019.02.017CrossRefPubMed

60.

Ren L (2024) The mechanistic basis for the rapid antidepressant-like effects of ketamine: From neural circuits to molecular pathways. Prog Neuro-Psychopharmacol Biol Psychiatry 129:110910. https://doi.org/10.1016/j.pnpbp.2023.110910CrossRef

61.

Shinohara R, Aghajanian GK, Abdallah CG (2021) Neurobiology of the rapid-acting antidepressant effects of ketamine: impact and opportunities. Biol Psychiatry 90(2):85–95. https://doi.org/10.1016/j.biopsych.2020.12.006CrossRefPubMed

62.

Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, Pereira EFR, Albuquerque EX, Thomas CJ, Zarate CA, Gould TD (2018) Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharmacol Rev 70(3):621–660. https://doi.org/10.1124/pr.117.015198CrossRefPubMedPubMedCentral

63.

Shirayama Y, Hashimoto K (2017) Effects of a single bilateral infusion of R-ketamine in the rat brain regions of a learned helplessness model of depression. Eur Arch Psychiatry Clin Neurosci 267(2):177–182. https://doi.org/10.1007/s00406-016-0718-1CrossRefPubMed

64.

Carreno FR, Donegan JJ, Boley AM, Shah A, DeGuzman M, Frazer A, Lodge DJ (2016) Activation of a ventral hippocampus-medial prefrontal cortex pathway is both necessary and sufficient for an antidepressant response to ketamine. Mol Psychiatry 21(9):1298–1308. https://doi.org/10.1038/mp.2015.176CrossRefPubMed

65.

Deyama S, Kondo M, Shimada S, Kaneda K (2022) IGF-1 release in the medial prefrontal cortex mediates the rapid and sustained antidepressant-like actions of ketamine. Transl Psychiatry 12(1):178. https://doi.org/10.1038/s41398-022-01943-9CrossRefPubMedPubMedCentral

66.

Ma S, Chen M, Jiang Y, Xiang X, Wang S, Wu Z, Li S, Cui Y, Wang J, ZhuY ZY, Ma H, Duan S, Li H, Yang Y, Lingle CJ, Hu H (2023) Sustained antidepressant effect of ketamine through NMDAR trapping in the LHb. Nature 622(7984):802–809. https://doi.org/10.1038/s41586-023-06624-1CrossRefPubMedPubMedCentral

67.

Yang Y, Cui Y, Sang K, Dong Y, Ni Z, Ma S, Hu H (2018) Ketamine blocks bursting in the lateral habenula to rapidly relieve depression. Nature 554(7692):317–322. https://doi.org/10.1038/nature25509CrossRefPubMed

Title: Ketamine and its enantiomers for depression: a bibliometric analysis from 2000 to 2023
Authors: Li-yuan Zhao
Guang-fen Zhang
Xue-jie Lou
Kenji Hashimoto
Jian-jun Yang
Publication date: 25-04-2024
Publisher: Springer Berlin Heidelberg
Keywords: Ketamine
Antidepressant Drugs
Antidepressant Drugs
Affective Disorder
Affective Disorder
Esketamine
Esketamin
Published in: European Archives of Psychiatry and Clinical Neuroscience
Print ISSN: 0940-1334
Electronic ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-024-01809-9

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Ketamine and its enantiomers for depression: a bibliometric analysis from 2000 to 2023

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content